We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$102M
AUM Growth
-$36.6M
Cap. Flow
-$55.2M
Cap. Flow %
-54.28%
Top 10 Hldgs %
98.25%
Holding
12
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$4.17M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$57.3M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$1.1M
3
PVLA
Palvella Therapeutics
PVLA
+$974K

Sector Composition

Rank Sector Weight
1 Healthcare 97.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$33.8M 33.22%
2,600,410
– –
SNNA
2
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$14.2M 14%
758,610
– –
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$13.5M 13.26%
1,000,000
– –
JNCE
4
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$11.8M 11.64%
529,965
-49,685
-9% -$1.1M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$7.16M 7.04%
551,477
– –
KYNB
6
Kyntra Bio
KYNB
$28.5M
$6.04M 5.93%
5,226
– –
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
$5.31M 5.22%
9,728
-1,573
-14% -$974K
EPIX
8
DELISTED
ESSA Pharma
EPIX
$4.12M 4.05%
1,084,848
+1,000,000
+1,179% +$4.17M
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.14M 2.1%
223,457
– –
EGLT
10
DELISTED
Egalet Corporation
EGLT
$1.82M 1.79%
2,889,926
– –
CDTX
11
DELISTED
Cidara Therapeutics
CDTX
$1.78M 1.75%
22,248
– –
JUNO
12
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-753,564
Closed -$57.3M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2018 Portfolio in Review

As of Q1 2018, Omega Fund Management held 12 positions worth $102M, down 26% from $138M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Omega Fund Management withdrew a net $55.2M in Q1 2018, closing 1 position and reducing 2 holdings. Its most notable exit was Juno Therapeutics, Inc., an estimated $57.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 74% a quarter earlier.

Against the trend, Omega Fund Management added an estimated $4.17M to ESSA Pharma.

  • Omega Fund Management added most to ESSA Pharma in Q1 2018, an estimated $4.17M increase.
  • Omega Fund Management's biggest Q1 2018 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $1.1M.
  • Omega Fund Management fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $57.3M.
  • Omega Fund Management's ten largest holdings make up 98% of its $102M portfolio in Q1 2018.
  • Omega Fund Management opened 0 new positions and closed 1 in Q1 2018.
  • Omega Fund Management's portfolio value fell 26% quarter-over-quarter to $102M.

Based on Omega Fund Management's 13F filing for Q1 2018, filed 4 May 2018.